Tag Archives: Virta

April 19-22 CHMP Agenda; EMPEROR-REDUCED Opinion?; Virta Health Raises $133M in Series E

Two cardiometabolic-related news items have been observed: the CHMP agenda for this month’s meeting (April 19-22, 2021) has been released and includes one notable item⁠, Jardiance HFrEF is listed under Type II Variations; and Virta Health announced it has raised $133M in a Series E equity financing round at a $2B valuation (up from $1.1B in December 2020). Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Virta Health Raises $65M in Series D Funding Round

Virta Health announced it raised $65M in a Series D funding round led by Sequoia Capital Global Equities and Caffeinated Capital which values Virta Health at >$1.1B. For context, Virta offers non-pharmaceutical coaching and lifestyle intervention program for chronic metabolic conditions, including T2DM, with the goal of improving patient health and reducing the need for some medications. Below, FENIX provides thoughts on Virta’s funding and valuation in the context of the recent Livongo/Teladoc merger as well as brief thoughts on the Virta value proposition.

This content is for Read Less members only.
Register
Already a member? Log in here